Novartis Wins MS Drug Approval in Russia

Swiss drugmaker Novartis revealed that it has won the approval for its multiple sclerosis drug, Gilenya in Russia

Swiss drugmaker Novartis revealed that it has won the approval for its multiple sclerosis drug, Gilenya in Russia and is expected to win the approval from the US Food and Drug Administration (FDA) later this month.

Gilenya is expected to rival Merck’s cladribine in Russia though Novartis is likely to beat its rival to the approval from the FDA after an overwhelmingly positive response from a number of health experts.

Multiple sclerosis - Symptoms - Causes - Diagnosis - Treatment
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses

Kepler Capital Markets analyst Tero Weckroth said that the approval by FDA could prove to be a major boost for Novartis’ sales in the US. “We expect U.S. approval in September. Although we are concerned about the speed of the sales growth after launch, the U.S. approval could be a positive trigger for Novartis”, Weckroth saib

Merck KGaA's cladribine has already received approval in Russia in July, but it now appears that Novartis may be ahead in the race for US approval.

Chemotherapy - History, Principles, Aim, Types, Side Effcts, Pros & Cons
'Chemo' means medicine or 'drug', 'therapy' means 'treatment'. Chemotherapy refers to the use of cytotoxic drugs in the treatment of cancer.

Source-Medindia

Study Reveals A Simple Blood Test That May Help Predict Severity Of Multiple Sclerosis
University College London scientists have revealed that a simple blood test may soon help predict the severity of multiple sclerosis (MS).

Texas Youth Commission Reeling Under Multiple Charges
The Texas Youth Commission’s facilities continue to reel under allegations of ward neglect and abuse, after the Dallas Morning News unearthed sordid details about the agency.